GI-102
- Generic Name
- GI-102
GI Innovation and LaNova Partner to Develop Novel Combination Therapy for Pancreatic Cancer
GI Innovation and LaNova Medicines have signed an MOU to develop a combination therapy using GI-102 and ADC LM-302 for pancreatic cancer treatment. The collaboration follows promising preclinical results showing excellent anticancer activity in pancreatic cancer models, potentially offering a new treatment option in an area with limited therapeutic choices.
GI Innovation Doses First Patient in Phase 1 Trial of Subcutaneous Immunotherapy GI-102 for Melanoma
• GI Innovation initiated a Phase 1 clinical trial of GI-102, a subcutaneous (SC) immune-oncology drug, marking the first such attempt by a Korean firm.
• The trial, conducted across 14 medical institutions in Korea and the U.S., evaluates GI-102's potential in treating melanoma and other indications.
• Preclinical data suggests GI-102's SC formulation may enhance efficacy compared to IV administration, showing a 30% objective response rate in metastatic melanoma patients.
• The Phase 1 trial is expected to conclude by February 2025, with global pharmaceutical companies showing interest in clinical data for potential technology licensing.
GI Innovation and MSD Collaborate on GI-102 and Keytruda Combination Trial for Resistant Cancers
• GI Innovation partners with MSD to evaluate GI-102 combined with Keytruda (pembrolizumab) in a Phase II trial.
• The trial targets metastatic liver cancer, melanoma, and renal cell carcinoma patients resistant to immunotherapy.
• GI-102 previously demonstrated a 42.9% overall response rate in melanoma patients unresponsive to standard treatments.
• The study will be conducted across 14 hospitals in South Korea and multiple sites in the US, including Mayo Clinic and Memorial Sloan Kettering.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath